# Ilika plc appoints Dr. Louise Turner as VP Product Development

- Link: https://www.directorstalkinterviews.com/ilika-plc-appoints-dr.louise-turner-as-vp-product-development/4121121753
- Published: 2023-06-16T07:12:58+01:00
- Author: Emily Johnson

**[Ilika Plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)**(
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)), a pioneer
in solid-state battery technology, today provided an update on senior appointments,
a notice of conversion of preference shares, total voting rights, and an update 
to staff share option awards.

**VP Product Development**

With effect from 1 September 2023, Ilika has appointed Dr. Louise Turner to the 
role of VP Product Development. Promoted from her current position as Technical 
Director, Louise has demonstrated her skills in overseeing both the scientific development
and scale-up activities of the Stereax_®_ product and can draw on both her Doctorate
in Chemistry and MBA in Business & Technology to further the Ilika story.

![Dr. Louise Turner Ilika VP](https://www.directorstalkinterviews.com/wp-content/
uploads/2023/06/Dr.-Louise-Turner.jpg "Ilika plc appoints Dr. Louise Turner as VP
Product Development (IKA)")

Louise will take over line management responsibility for Ilika’s Stereax and Goliath
product development programmes from Robin Bell. Robin will continue to work with
and support the Company in an advisory capacity as New Product Introduction Director
where he will continue supporting each product in its journey to market.

> **Ilika’s CEO Graeme Purdy,** **stated:** _“We are delighted to have the opportunity
> to promote such a capable leader and scientist as Louise to the senior management
> team. Louise will build on the product development and commercialisation work 
> that she has delivered with the Stereax team to the wider business helping to 
> enact the same scale up and delivery in the Goliath product roadmaps. We look 
> forward to continuing our relationship with Robin in his new technical consulting
> role.”_

**Conversion of preference shares**

Ilika announces that following receipt of conversion notices in relation to 426,300
convertible preferred Ordinary Shares of one penny each, it has today issued 426,300
Ordinary Shares. Accordingly, the Company has applied to the London Stock Exchange
for 426,300 Ordinary Shares to be admitted to trading on AIM. It is expected that
Admission will occur at 8:00 a.m. on 19 June 2023.

**Total Voting Rights**

Following Admission, the Company’s issued share capital will comprise 158,900,667
Ordinary Shares and that number may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are required
to notify their interest in, or a change in their interest in, the share capital
of the Company under the FCA’s Disclosure Guidance and Transparency Rules. The Company
does not hold any shares in treasury. ** **

**Award of share options update**

The Company also announces that as part of the Company’s EMI option scheme, in addition
to the 802,248 options granted over ordinary shares of one penny each in the Company(“
Ordinary Shares”) on 1 March 2023, the Company awarded an additional 350,138 market
value options to employees on 1 March 2023. Therefore, an aggregate of 1,572,140
options over Ordinary Shares had been granted to employees under the EMI option 
scheme on 1 March 2023, representing 0.99% of issued share capital.

Share on:
